Correlation Between GVHD Prophylaxis and Lymphocyte Counts on Day 29
| GVHD Prophylaxis . | Lymphocytes <0.2 × 109/L No. of Patients (%) . | Lymphocytes ≥0.2 × 109/L No. of Patients (%) . | Day 29 Lymphocytes (109/L) Median (range) . |
|---|---|---|---|
| T-cell depletion | 4 (33) | 8 (67) | 0.34 (0-1.52) |
| Cyclosporine alone | 25 (20) | 100 (80) | 0.48 (0-5.87) |
| Cyclosporinemethotrexate | 6 (12) | 45 (88) | 0.53 (0.08-2.82) |
| P | .18 | .50 (TCD v Cy) | |
| (Chi squared) | .14 (TCD vCy-MTX) | ||
| .19 (Cy vCy-MTX) (ANOVA) |
| GVHD Prophylaxis . | Lymphocytes <0.2 × 109/L No. of Patients (%) . | Lymphocytes ≥0.2 × 109/L No. of Patients (%) . | Day 29 Lymphocytes (109/L) Median (range) . |
|---|---|---|---|
| T-cell depletion | 4 (33) | 8 (67) | 0.34 (0-1.52) |
| Cyclosporine alone | 25 (20) | 100 (80) | 0.48 (0-5.87) |
| Cyclosporinemethotrexate | 6 (12) | 45 (88) | 0.53 (0.08-2.82) |
| P | .18 | .50 (TCD v Cy) | |
| (Chi squared) | .14 (TCD vCy-MTX) | ||
| .19 (Cy vCy-MTX) (ANOVA) |
Thirteen patients had either died by day 29 (n = 9) or had no lymphocyte counts available for that day (n = 4). None of the differences is significant.